澳大利亚专利AU2013201287A1 Synthetic regulation of gene expression

专利PDF首页>>澳大利亚专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Atty docket no. 32455/AU-1/ORD Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided. -~ a w C, C.) 0 c~ - = 0 - 0 U) C 0 U o 0 .~ I-0 0 .~ _ 0 C.) 0 C .- C co h. 0
公开号:AU2013201287A1
申请号:U2013201287
申请日:2013-03-04
公开日:2013-09-26
发明作者:Mariano A. Garcia-Blanco；Matthew S. Marengo
申请人:Duke University；
IPC主号:C12N15-79

专利说明:
S&F Ref: P064474 AUSTRALIA PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT Name and Address Duke University, of 2812 Erwin Road, Suite 306, of Applicant: Durham, North Carolina, 27708, United States of America Actual Inventor(s): Matthew S. Marengo Mariano A. Garcia-Blanco Address for Service: Spruson & Ferguson St Martins Tower Level 35 31 Market Street Sydney NSW 2000 (CCN 3710000177) Invention Title: Synthetic regulation of gene expression The following statement is a full description of this invention, including the best method of performing it known to me/us: 5845c(7189096 1) Atty aocKei no. iL43/AU-./UnU SYNTHETIC REGULATION OF GENE EXPRESSION (001) This application claims the benefit of U.S. Provisional Application No. 61/607,312, filed March 6, 2012, which is incorporated herein by reference in its entirety for any purpose. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH (002) This invention was made with government support under Federal Grant Nos. IF32CA142095 and R01CA127727, both awarded by the National Institutes of Health: National Cancer Institute. The government has certain rights in the invention. BACKGROUND (003) Current work in synthetic biology is focused on modifying protein structure and function, and regulation of gene expression circuits at the level of transcription promoters (Kwok, 2010). While promoter control of expression may be sufficiently specific in bacterial systems, heterologous promoters confer only limited control of gene expression (e.g. cell specific expression) in eukaryotic cells, possibly because of a lack of correct chromatin assembly (Wolffe, 1999). The limited control of gene expression in eukaryotic cells by heterologous promoters alone may be insufficient for certain therapies and other biotechnological applications. Complete spatiotemporal control of gene expression is important for the use of at least a subset of biological molecules in gene therapy and other biotechnological applications. SUMMARY (004) In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct comprises a cell-specific promoter, a heterologous gene, and a cell-specific exon. In some embodiments, the cell-specific exon is excluded in the cell in which the cell-specific promoter is most active. In some embodiments, inclusion of the exon results in the product of the heterologous gene being inactive, or no product of the heterologous gene being produced. In some embodiments, inclusion of the exon results in a frame shift in the heterologous gene or a stop codon before or within the heterologous gene, or both. (005) In some embodiments, the cell-specific exon is included in the cell in which the cell-specific promoter is most active. In some embodiments, exclusion of the exon results in the product of the heterologous gene being inactive, or no product of the heterologous gene being produced. In some embodiments, exclusion of the exon results in a frame shift in the heterologous gene or a stop codon before or within the heterologous gene, or both. (006) In some embodiments, a synthetic regulatory construct comprises a cell-specific RNA stability element. In some such embodiments, the cell-specific RNA stability element is a microRNA target sequence. 1 Atty docket no. 32455/AU-1/ORD (007) In some embodiments, a cell-specific promoter is at least 2-fold, at least 3-fold, at least 5-fold, at least 7-fold, or at least 10-fold more active in a selected cell than in at least one other cell comprised in the same organism as the selected cell. In some embodiments, a cell-specific promoter is at least 2-fold, at least 3-fold, at least 5-fold, at least 7-fold, or at least 10-fold more active in a selected cell than in at least two, at least three, or at least five other cells comprised in the same organism as the selected cell. In some embodiments, a cell-specific promoter is at least 2-fold, at least 3-fold, at least 5-fold, at least 7-fold, or at least 10-fold more active in a selected cell than in any other cell comprised in the same organism as the selected cell. (008) In some embodiments, a cell is an animal cell. In some embodiments, a cell is a mammalian cell. In some embodiments, the mammal is selected from human, mouse, rat, dog, chimpanzee, and monkey. In some embodiments, a cell is a plant cell. In some embodiments, a plant is selected from a monocot and a dicot. In some embodiments, a cell is a fungal cell. (009) In some embodiments, cells comprising synthetic regulatory constructs are provided. In some embodiments, a cell is an animal cell. In some embodiments, a cell is a mammalian cell. In some embodiments, a cell is comprised in a mammal. In some embodiments, a cell is ex vivo or in vitro. In some embodiments, a cell is a plant cell. In some embodiments, a cell is comprised in a plant. In some embodiments, a cell is a fungal cell. (0010) In some embodiments, methods of expressing a heterologous gene in a selected cell are provided. In some embodiments, a method comprises introducing a synthetic regulatory construct into the selected cell. In some embodiments, a cell is an animal cell. In some embodiments, a cell is a mammalian cell. In some embodiments, the mammal is selected from human, mouse, rat, dog, chimpanzee, and monkey. In some embodiments, a selected cell is selected from mesenchymal, epithelial, neuronal, heart muscle, skeletal muscle, smooth muscle, and embryonic muscle cells. In some embodiments, a cell is comprised in a mammal. In some embodiments, a cell is a plant cell. In some embodiments, a cell is comprised in a plant. In some embodiments, a cell is a fungal cell. DESCRIPTION OF THE FIGURES (0011) Figure 1 shows (A) schematic diagrams of four plasmids with various elements for synthetic regulation of firefly luciferase expression, and (B) expression of firefly luciferase in mesenchymal and epithelial cells transfected with the plasmids from (A), as described in Example 1. (0012) Figure 2 shows (A) a schematic diagram of a plasmid designed for epithelial-cell specific expression of Cre recombinase (Cre), and the predicted spliced products and translation products resulting from that plasmid in mesenchymal and epithelial cells, and a second plasmid 2 Atty docKet no. iZ4JJ/AU-1/UKU that expresses dsRED in the absence of Cre protein and EGFP in the presence of Cre protein; (B) fields of mesenchymal and epithelial cells transfected with the plasmids from (A), showing expression of dsRED (left panels) and EGFP (right panels); and (C) quantitation of EGFP expression in mesenchymal and epithelial cells transfected with the plasmids from (A) over time, as described in Example 2. (0013) Figure 3 shows (A) a schematic diagram of a plasmid designed for epithelial cell specific expression of diphtheria toxin, and the predicted spliced products and translation products resulting from that plasmid in mesenchymal and epithelial cells; and (B) detection of transcripts resulting from the plasmid from (A) in transfected mesenchymal and epithelial cells, as described in Example 3. (0014) Figure 4 shows (A) a schematic diagram of a plasmid designed for mesenchymal cell-specific expression of a protein x, and four predicted spliced products resulting from that plasmid in mesenchymal and epithelial cells; and (B) detection of transcripts resulting from the plasmid from (A) in transfected mesenchymal and epithelial cells, as described in Example 4. DETAILED DESCRIPTION (0015) The present inventors have developed a synthetic gene regulation system that provides better spatiotemporal regulation than promoters used alone. In some embodiments, the synthetic gene regulation system described herein provides better cell-specificity than cell specific promoters used alone. in some embodiments, the synthetic gene regulation system described herein provides better temporal regulation than certain promoters used alone. In some embodiments, the synthetic gene regulation system may be used for cell-specific and/or temporal regulation of expression of various agents, including, but not limited to, therapeutic agents. Accordingly, in some embodiments, artificial control of the expression of biological molecules, including, but not limited to, therapeutic biological molecules, via combinations of cell-specific promoters, cell-specific exons and cell-specific RNA stability elements, is provided. In some embodiments, artificial control of the expression of biological molecules, including, but not limited to, therapeutic biological molecules, via combinations of temporally-regulated promoters, temporally-regulated exons and temporally-regulated RNA stability elements, is provided. In some embodiments, such modular regulatory elements may come from different genes or be artificial combinations of known sub-elements. (0016) As described herein, post-transcriptional regulation offers additional control of gene expression, particularly in eukaryotic cells. For example, in some embodiments, alternative cassette exons may either be included or skipped in eukaryotic mRNA in a cell specific manner ("cell-specific exons"). In some embodiments, alternative exon inclusion may disrupt the expression of, or change the function of, a gene product. Like transcription 3 Atty docket no. iL455/AU-1/UKU promoters, exons are recognized by regulatory macromolecular complexes in the cell. Further, this recognition may be modular: exons may be moved into heterologous contexts and still be recognized by the cell. (0017) As a further example, in some embodiments, post-transcriptional regulation can determine the stability of mRNAs in a cell-specific manner ("cell-specific RNA stability elements"). In some embodiments, by affecting RNA stability, such post-transcriptional regulators may determine RNA levels. This regulation may also be accomplished by an independent set of macromolecular complexes. In some embodiments, regulation of RNA stability involves small non-coding RNAs known as microRNAs (miRNAs). In some embodiments, mRNAs may be regulated at the level of translation efficiency, for example, by proteins and miRNAs, which may exert their function via signals in the 5' and/or 3' untranslated regions (UTRs) of the messenger. (0018) As discussed herein, in some embodiments, the various levels of regulation (including, but not limited to, transcription, alternative splicing, and RNA stability) are orthogonal and thus provide independent modes that in combination provide multiplied specificity. Thus, in some embodiments, by combining modular control elements from different genes, novel or artificially stringent patterns of gene expression can be engineered. Currently, such modular control does not appear to be appreciated in synthetic biology. Definitions (0019) The subject matter disclosed herein is described using several definitions, as set forth below and throughout the application. (0020) Unless otherwise noted, the terms used herein are to be understood according to conventional usage by those of ordinary skill in the relevant art. In addition to the definitions of terms provided below, it is to be understood that as used in the specification, embodiments, and in the claims, "a", "an", and "the" can mean one or more, depending upon the context in which it is used. (0021) As used herein, "about," "approximately," "substantially," and "significantly" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which they are used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, "about" or "approximately" will mean up to plus or minus 10% of the particular term and "substantially" and "significantly" will mean more than plus or minus 10% of the particular term. (0022) As used herein, the terms "include" and "including" have the same meaning as the terms "comprise" and "comprising." 4 Atty docket no. 32455/AU-1/ORD (0023) As used herein, the term "cell-specific promoter" refers to a promoter that is at least 3-fold more active in a selected cell than in one or more other cells. In some embodiments, a cell specific promoter is at least 4-fold, at least 5-fold, at least 6-fold, at least 7 fold, at least 8-fold, at least 9-fold, or at least 10-fold more active in a selected cell than in one or more other cells. In some embodiments, a cell specific promoter is at least 3-fold, at least 4 fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10 fold more active in a selected cell than in other cells found in the same organism as the selected cell. In some embodiments, a selected cell is a particular cell type. (0024) As used herein, the term "cell-specific exon" refers to an exon that is present in a transcript or absent from a transcript through alternative splicing at a rate that is at least 3 fold greater in a selected cell than in one or more other cells. In some embodiments, a cell specific exon is present in a transcript in a selected cell at a rate that is at least 3-fold, at least 4 fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10 fold greater than it is present in a transcript in one or more other cells. In some embodiments, a cell-specific exon is absent from a transcript in a selected cell at a rate that is at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than it is absent from a transcript in one or more other cells. In some embodiments, a cell-specific exon is present in a transcript in a selected cell at a rate that is at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than it is present in a transcript in in other cells found in the same organism as the selected cell. In some embodiments, a cell-specific exon is absent from a transcript in a selected cell at a rate that is at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than it is absent from a transcript in other cells found in the same organism as the selected cell. In some embodiments, a selected cell is a particular cell type. (0025) In some embodiments, the rate that an exon is present is determined as the ratio of spliced transcript with the exon present to spliced transcript with the exon absent in a particular cell. In some embodiments, the rate an exon is absent is determined as the ratio of spliced transcript with the exon absent to spliced transcript with the exon present in a particular cell. As a nonlimiting example, the following table shows hypothetical rates that a hypothetical cell-specific exon A is present in a transcript in hypothetical cells x and y: Relative amount Relative amount Rate exon Fold difference in rate of transcript of transcript with is included of inclusion in cell x with exon A exon A excluded versus cell y included Cell x 10 2 5 Cell y 5 10 0.5 10-fold 5 Atty docket no. 32455/AU-1/ORD (0026) As used herein, the terms "exclusion", "excluded", and similar terms, when used in relation to an exon, mean that the rate that an exon is included in a transcript, as described above, is less than 1. Alternatively, the terms "exclusion", "excluded", and similar terms, when used in relation to an exon, mean that the rate that an exon is excluded from a transcript, determined in a similar manner as described above for inclusion of an exon (although with the numerator and denominator reversed), is greater than 1. (0027) As used herein, the terms "inclusion", "included", and similar terms, when used in relation to an exon, mean that the rate that an exon is included in a transcript, as described above, is greater than 1. Alternatively, the terms "inclusion", "included", and similar terms, when used in relation to an exon, mean that the rate that an exon is excluded from a transcript, determined in a similar manner as described above for inclusion of an exon (although with the numerator and denominator reversed), is less than 1. (0028) As used herein, the term "heterologous gene" refers to any gene or coding sequence that is not controlled in its natural state (e.g., within a non-genetically modified cell) by the cell-specific promoter to which it is operably linked in a particular construct, and whose gene, in its natural state, does not contain the cell-specific exon included in the particular construct. In some embodiments, the gene or coding sequence is described as being heterologous to the cell-specific promoter and/or heterologous to the cell-specific exon. (0029) As used herein, the terms "cell-specific RNA stability element" and "cell-specific RNA stability element" refer to a regulatory element, which may be in the 3'-untranslated region or 5'-untranslated region of a transcript, that increases the stability or translation of a transcript in a selected cell and/or decreases the stability or translation of the transcript in one or more cells other than the selected cell, such that the stability or translation of the transcript in the selected cell is at least 2-fold greater than the stability or translation of the transcript in one or more other cells. In some embodiments, the stability or translation of the transcript in the selected cell is at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than in one or more other cells. In some embodiments, the stability or translation of the transcript in the selected cell is at least 2-fold, 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9 fold, or at least 10-fold greater than in other cells found in the same organism as the selected cell. In some embodiments, a selected cell is a particular cell type. In some embodiments, an RNA stability element is an element that decreases the stability or translation of the transcript in one or more cells other than the selected cell. In some embodiments, a cell-specific RNA stability element is a microRNA target sequence. In some embodiments, a cell-specific RNA 6 Atty docket no. 32455/AU-1/ORD stability element is a binding site for an hnRNP protein. Nonlimiting exemplary hnRNPs include AUF-1, AUF-2, and HuR. (0030) The term "microRNA target sequence" refers to a RNA stability element that comprises a seed match sequence for a particular microRNA. A seed match sequence is a sequence that is complementary to at least nucleotides 2 to 7 of the microRNA. In some embodiments, a microRNA target sequence comprises a sequence that is complementary to more of the microRNA than just nucleotides 2 to 7. In some embodiments, a microRNA target sequence decreases the stability or translation of a transcript in cells that express the particular microRNA. Nonlimiting exemplary cell-specific promoters (0031) Many cell-specific promoters are known in the art. Nonlimiting exemplary mammalian cell-specific promoters have been characterized and used in mice expressing Cre recombinase in a cell-specific manner. See, e.g., http://jaxmice.jax.org/list/xprscreRT.html#xprsl80l. Certain nonlimiting exemplary mammalian cell-specific promoters are listed in Table 1. 7 E - (4- >)~ >0 CL u r-.7 4 ~. . c- c *t a J u ~ ~ c - - oa -=c o a u C a) c a).:) 3 0 ., _ -o m -o a ... n y a - - e n a - -' <) '5 * a0-0 .) a' = .C=)U m -:: u c 3 -0 c = Me a>) - * o r a) -o Ea E. u a)< ) - : ) M) 0 - a)( c 0 (u 0 000- 0 - o w m o e cVa~ a> , 0 c EU a E E.-2 ._ a)~ O a mJ c) *x -0 m oC 0 - co Eo > r -C 0) a) 00 o . N ' E A wc S o '_ = m- m 0 0 0 o m E- - o ' -. c c..c -c o u u 2 u 0 oo 0 a) .. a a a) a) EE E, E -'S 0o 00 2 o o - m .. -w E CL CC 4-.e 0 .... a a)C CVa) En c ~0 u- m .- CL 0> 0E E0-. E0o -E - -0 ' 0. o m0. m a - . 0 to _ X 4 r- n .- - E: 0 > -- ~ .2 aa) Cc a) -o S ,- - m o F > c CL (xN r-o >u m0 C >m w = 5 D * C aU . EE 0- -m E t o o E z> OW - E * z c 0 * 0 o 0 a~ a) z wx no '- Ec E E - o > = -w c c) -_ (u m --- m. -o Z00 (UV a) o~ o -r _ -CC s 0 E CC (Va) V)) : .n L oE 0 -o E E < Q) omzo 'T - E) zm a 0. < 0 -v CV M 4 ro J3 cC CU_ U E~*U a)~ ~ -u (u Ln -c 0 CC Q) -0 c -;,- ~4 U C U a (V- a) uo .2 ';: E )~). 2 V2 0m O 0 Con C O - O Go)00 2U m - 22 2a) 0 00. :3c- C 0 E 0 a) 4 :: 0- a) U c -) ( Q0.
U-. UD U 0 O- c u U~~b a)V-a " 0L m -0~a a) a) CV >4s U V ( 0 0 cCm >- C 00V )- 2 a 00 u -0 UJ a)a a) a) C U - C a) r- 0 w U 0L J C- C Ca) " 0 a)' ) u c a)w oo - C W 0CV 0 0 aj 2 E ) o c _ 0-V44 :E2 m ) E -0 a) ) :3Za w E ( E4a a) -0 a)0 C5 E a) n E E>w0a) a)) C a)0 0 _ a 2m C f EC to V 0 cu 0.Ua -C X 0 (J0 I.t
UL
C W -~~ -2 .
CA(( oC 0 E~ W( ~ ~ 3 0 J0 0 a0~ E Ln -0 0 ( 0 0> -C u C "DE ~E 0> Cw EE LO)~- 0075- 0_ W 00 u- C 2: 0)_ 0 0o Em o- 0 " 00Mc EC (A c 000 C c Eo~ W C E E~~0 -" U0 ua V)A0 C 40~ >- 0)CO C > 0C 0 0 E cu E 0 0 0W W W E w > V)) u(A xj o 0-oce'm -) r ) C 0 0E mE E0E .j -C CL CL Z OCu aa m a - (0 0 w Cj C o LA w0)C -r -; >- c E CL m C >. m >m >> r,. E 2D *u m 00 a ) 300 (0 (AL m cu CL4 a . U E . 0 0) A (0 (A ( 0 a.- c ) c 0 ) E a ( 04a) 00) a 0 m 0 = 0 E A Ln n a Em Ec 0) c r 0 0 " > C j Z .9 -* = -a E >*- o c) : 0 L -- a, '.CL 30 -0 WC 0 u 0 L W a o0( 04- U0 uw C 0 0 w c u > -~ Lr 0 ~ 0~. _ o~ -C -C"~ ~ 0r u m -o- t a 2 C =m cE 0 ( e o ) c x' (U UT . U . a.) W. = C ~ 7c o3 - Eo=o E u u. M (A -M 0 CLL E - . E oo 2- 5E oV -C mc u (5 o EL m 0 c~ E -c -- 0 oU o (U 0 0 ( ' > + n) - CC 0 0 m .C. E. c -C - c m . 0 (U0 -~ EE o , , 2 E o 0 0 , 2 oa 4 ,e- C E E -1 -- o ..- A .- A ,. 2c . -a 0..c 4-n Cm a) c , ,- .p m -2 O C .o - .. S. C C o .
-0 0m 0 0A 0 c ) X c Q - x -- E > o CcC CL o o - g ~ - o o r o * E a e o o 3 c >c 0 as > a.. noC o C - 2 e u 0 0 -" C CL 0 - 0 no - 0 -A =. c .. - "2 c -O O o o -) Wc .2 - (.9o m 0 -n -D 0 .c- m= m E - > , w .. a D > - 0> - u = O o o - E = "C0 0 -c E ::o 0- > . o C - i> a -o - a )a c .- -U E m 0 - c. 0~ oc ED o.E . ..,. : c o E E E3 0c- E o u~ (U -o aj - -m E; wno- -c 'E E - c E - o o- E- :W E- E Qj ~ c~ m jV M- am tt CO -M-= 4 E m E c m 0 :E E 6- mmE m (A-I x -c c .aLo o o =- a4 o c * -i m- o.. .0 _r_ 0 - -. o-y .. 0 c - -- o o E- o a) C 0 CLC ou m ~ mu ~ c E E c E EJ o >a E - w C .. U w 0 0 as a ) z u EC o cC 0C> a _E -- Z oCo - 1. -a -o> = xUa> a e .r'4r-. .o 2o o -00 - a cz C' r yC E 3r 0 E o Q ZyC E o to x o . - . C. o r E E E 2 .c E Q. ov CL 76 >a. -E 3-FaA-a C > c - 0 c - = C C C E 0 0 a)00c u .. . - .... , as o . ! c g o m ~ -) -a :3 E wu E c 00 C -' ' 0 - - o r / 0E E C o a)- c 4-0 A D . m C - E 0 --. ) c m ..- A .. .- A u) E 0) 00 CW 0 ) 0 E - c- C> 7a E 0 oo C0 -0 Q) 00E=u0-u L m 0!, C Q) u- -w 0 V L4 - 0 M ) "E 0- -0 - o> 3: CLQ) : Lm.4m NotoC= 0r mL02-2 ~ O E U, M 0 -Fa u - a- E >. o~c LU (V U U w 0 c 0 0 0V 0~ 0 0 C C 2 - 00 x E 0 0 I r4 -r c .2 c- S~ 0) U, (V 0) 0)0 00 Q,~W4~ 0
-~
4
-
u =0 (N"" OD C (u 00 C aj a 0 -C M 4-)~ U 0 -0.~ 0 Atty docket no. 32455/AU-1/ORD (0032) In some embodiments, a cell-specific promoter is a promoter that is active in plants. Many exemplary cell-specific plant promoters are known in the art. See, e.g., U.S. Patent Nos. 5,097,025; 5,783,393; 5,880,330; 5,981,727; 7,557,264; 6,291,666; 7,132,526; and 7,323,622; and U.S. Publication Nos. 2010/0269226; 2007/0180580; 2005/0034192; and 2005/0086712, which are incorporated by reference herein in their entireties for any purpose. Nonlimiting exemplary cell-specific exons (0033) Many cell-specific exons are known in the art. Certain nonlimiting exemplary cell-specific exons are described in Table 2 and in the examples provided herein. The literature references provided in Table 2 are each incorporated by reference herein in their entireties for any purpose. (0034) In some embodiments, a cell-specific exon is included in a selected cell. In some embodiments, the inclusion of the cell-specific exon allows for expression of an active product from a heterologous gene into which the exon is incorporated. In some embodiments, the inclusion of a cell-specific exon results in expression of an inactive product from a heterologous gene. In some embodiments, the inclusion of a cell-specific exon results in a decrease or elimination of expression of the heterologous gene product, for example, by inserting a stop codon upstream of the start codon of the heterologous gene and/or by frame shifting the heterologous protein coding region. (0035) In some embodiments, a cell-specific exon is excluded in a selected cell. In some embodiments, the exclusion of the cell-specific exon allows for expression of an active product from a heterologous gene into which the exon is incorporated. In some embodiments, the exclusion of a cell-specific exon results in expression of an inactive product from a heterologous gene. In some embodiments, the exclusion of a cell-specific exon results in a decrease or elimination of expression of the heterologous gene product, for example, by frame shifting the heterologous gene coding region. 13 ~ (V ou a) a) 00 4 4- i c C. c C -C -C cu~ ~ a)O E O m ( ->-~ ( ( a) ) .~iC(VV Ff C- (C a) a) 0.t h CD> m -0.o~ M E '- " c 0~~o - 0 0- M CC. 4N 0 ~ a ~ i -C r 0.CO (N CO C c ( N 0 0 ~I- -4 a) (V'(o- U2 uN .0-: )-0 . C,4 a OaD)-- CV ) wt cr cO m~( *0)4- M .. C -C m a)C(U CV (V 4
,
4 C = 0 OC 4 O>O C .U r 0 C rV) a) a) 0)c ua -0 a) (u > Q aa) " 4- 5- a) Q) o oC c (A u ) a)c u U E mo 0 -> C <L U co u. 0 0)OC O. 0 U 0 a) Za a)a)U 5V -0 (A m( ~ U Ln )~ a a (j ~w a) ,. C aU- -. m < < V a) > ( 4- - a) : C a) Ea r4 >" E Dr 4- CL z 4- z L U, (U a) a. a) -c a a)D Uo 0- 0 -FD E00 E 0. m a) >. U23E E u 0 C 0 c .- -C c 0 > 0 m C4 a mV (U c o~- u U4- C WE a) HoW Eu o) z z u u w o E u. a) 0. c -C (U E CL 0 c. x + 0. x E ( 0 (V-r aj - c~ 0IC Cm ~ca 0 2) -Ef x x . ac oa) 00 (NO (NOLr CL 4- -a x I ) Q)x 'U0( xcw a oL C C V 0 ~ a) - a r 0L C
O..
0 0 x- ~ ' V UI (V x 0 xj CA.( w~(I 0) (V a) c L 0U 00 C 0 0 c J U, C 1L 4-V C u L .Eo (V x L a) m u' Z 0 . o~ > 0.> 0- . CL 0. m E L 0) 0) 0 u - 0. a)j -O Cu- 0 (V a) 4 ) N rl ma) 2 c .c I- LLu LL E C (UU 0.). E ) <rr U U < Z D<r .4- < ( (D ( -o .f 40 < < u U ulD S U a4) < (DL 1 I Atty docket no. 32455/AU-1/ORD Nonlimiting exemplary cell-specific RNA stability elements (0036) Various cell-specific RNA stability elements are known in the art. In some embodiments, a cell-specific RNA stability element is a microRNA target site. Many cell-specific microRNAs are known in the art. Nonlimiting exemplary mammalian cell-specific microRNAs are shown in Table 3. (0037) In some embodiments, a cell-specific microRNA is a plant microRNA. Table 3: Nonlimiting exemplary cell-specific microRNAs microRNA Cell/tissue specificity microRNA Tissue specificity miR-1a,d heart miR-122 liver miR-124a,b brain miR-219 brain Let-7c midbrain miR-154 brain miR-375 Pancreatic islets miR-125a,b brain miR-128a,b brain miR-127 brain miR-10a,b Kidney miR-218 Brain miR-30a-3p Kidney, lung, muscle miR-204 Brain miR-148a liver miR-133a,b Heart, muscle miR-208 Heart miR-215 Intestine miR-194 Intestine, kidney, liver miR-31 Intestine, liver miR-141 Intestine, kidney, lung miR-10a Intestine, kidney, lung, spleen miR-150 spleen miR-142-5p,3p spleen miR-126 Endothelial cells miR-155 Hematopoietic cells miR-142 Hematopoietic cells miR-181 Hematopoietic cells miR-223 Hematopoietic cells miR-140 cartilage miR-206 muscle 16 Atty docket no. 32455/AU-1/ORD Nonlimiting exemplary constructs (0038) In some embodiments, a construct for synthetic regulation of gene expression is provided. In some such embodiments, the construct comprises a cell-specific promoter and a cell-specific exon. In some embodiments, the construct further comprises a cell-specific RNA stability element. (0039) In some embodiments, a construct may further contain one or more additional elements that facilitate the propagation, use, and/or functioning of the construct, such as, without limitation, one or more coding sequences for selectable markers, one or more origins of replication, localization domains, etc. Elements for use in constructs for in vitro and in vivo gene expression are known in the art, and one skilled in the art can select suitable elements to include in a construct for synthetic regulation of gene expression described herein. In some embodiments, the selected elements facilitate the propagation, use, and/or functioning of a construct in a mammal. In some embodiments, the selected elements facilitate propagation, use, and/or functioning of a construct in a plant. In some embodiments, an element facilitates propagation of a construct in vitro, although the construct is intended for use in vivo. Nonlimiting exemplary methods (0040) In some embodiments, methods of synthetic regulation of gene expression in a cell, mammal, or plant are provided. In some embodiments, methods of cell-specific expression of a gene in a cell, mammal, or plant are provided. In some embodiments, a method comprises introducing into a cell, mammal, plant, or introducing into a selected cell in a mammal or plant, a construct comprising a cell-specific promoter, a heterologous gene, and a cell-specific exon, under conditions allowing expression of the heterologous gene in the selected cell. In some embodiments, a construct further comprises a cell-specific RNA stability element. (0041) In some embodiments, the heterologous gene is expressed in the selected cell at levels at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7 fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than it is expressed in one or more other cells of the same organism. In some embodiments, the heterologous gene is expressed in the selected cell at levels at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6 fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than it is expressed in other cells of the organism. In some embodiments, the heterologous gene is expressed in a set of selected cells at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold greater than it is expressed in other cells of the organism. A set of selected cells may be any combination of cells in which a particular construct will express a heterologous gene. Nonlimiting exemplary sets of cells 17 Atty docket no. 32455/AU-1/ORD include, but are not limited to, cells of the cortex, hippocampus, and cerebellum; epithelial cells located in various tissues (such as kidneys and mammary glands); and muscle cells located throughout the body (such as skeletal muscle). (0042) In some embodiments, a method comprises gene therapy in a mammal. In some such embodiments, the method allows expression of a heterologous gene in a selected cell type, with little or no expression of the heterologous gene in one or more other cell types. In some embodiments, a method comprises creating a transgenic animal. In some embodiments, a method comprises creating a transgenic plant. In some such embodiments, the method allows expression of a heterologous gene in a selected cell in the plant, with little or no expression of the heterologous gene in one or more other cells in the plant. In some embodiments, a method comprises creating transgenic fungi, for example, for temporal control of gene expression. (0043) In some embodiments, the heterologous gene is expressed at a higher level in a selected cell and/or is expressed at a lower level in one or more other cells, than it would be expressed if it were only under the control of a cell-specific promoter. (0044) The following examples are illustrative and are not intended to limit the claimed and/or disclosed subject matter. EXAMPLES Example 1: Synthetic regulation of gene expression in mesenchymal and epithelial cells (0045) To demonstrate synthetic regulation of gene expression, a set of plasmids was designed that would provide differential expression of firefly luciferase in mesenchymal and epithelial cells. As shown in Figure 1A, four plasmids were designed. The control plasmid, pFFint, contains a firefly luciferase gene with a single intron that is spliced in both mesenchymal and epithelial cells, under the control of a CMV promoter, which is also active in both mesenchymal and epithelial cells. Plasmid pFFIlic also contains a firefly luciferase gene under the control of a CMV promoter, but the gene contains the FGFR2 exon Illc, which is efficiently spliced out in epithelial cells, but included in mesenchymal cells, resulting in an interruption of the luciferase open reading frame. Plasmid pE-Cad FFint contains a firefly luciferase gene with a single constitutive intron that is spliced in both mesenchymal and epithelial cells, but is under the control of the E-cadherin promoter, which is more active in epithelial cells than mesenchymal cells. Plasmid pE-cad-FFIIIc contains a firefly luciferase gene with the regulated FGFR2 exon Illc, under the control of the E-cadherin promoter. (0046) Mesenchymal-like rat prostate cancer cells, AT3 cells, and epithelial-like rat prostate cancer cells, DT cells, were grown (separately) in 6-well plates overnight in low glucose DMEM. DT and AT3 cells are described, for example, in Tennant et al. (2000). Each type of cell 18 Atty docket no. 32455/AU-1/ORD was transfected with 50 ng of each of the plasmids shown in Figure 1A, along with 10 ng of a constitutive renilla luciferase as a transfection control, and 1.95 pg pUC19 as carrier DNA. The cells were incubated at 37*C overnight following transfection. The cells were then lysed and lysates were cleared by centrifuging for 10 minutes at 20,000 rcf (relative centrifugal force, or xg) at 4*C. Luciferase activities in the cell lysates were determined using the Dual Luciferase Assay System (Promega, Madison, WI). The firefly signal was divided by the control renilla signal for each plasmid / cell combination. (0047) The results of that experiment are shown in Figure 1B. Similar firefly luciferase activities were observed for mesenchymal and epithelial cells transfected with control plasmid FFint. Firefly luciferase expression was higher in epithelial cells than in mesenchymal cells transfected with either plasmid FFIIIc ("FF3c" in Figure 1B) or plasmid E-Cad FFint. The greatest expression difference was provided by plasmid E-Cad FFIIIc ("E-Cad FF3c" in Figure 1B), which contains both an epithelial-specific splicing cis-acting elements and an epithelial-specific promoter. These results demonstrate that by providing two levels of control, such as a cell specific promoter and a cell-specific intron, greater expression differentials between cell types can be obtained. Example 2: Synthetic regulation of gene expression in mesenchymal and epithelial cells using a Cre/Lox system (0048) A system was designed to provide synthetic regulation of Cre expression in mesenchymal and epithelial cells, which would lead to a color change from red to green predominantly in epithelial cells. Figure 2A shows the E-cadCrelllc plasmid, which contains a Cre gene with the FGFR2 exon IlIc, under the control of the E-cadherin promoter. In mesenchymal cells, an inactive Cre fusion with FGFR2 exon Illc will be expressed, which in epithelial cells, the FGFR2 exon IlIc will be spliced out and an active Cre protein will be expressed. The RG plasmid is also shown, which contains a dsRED gene flanked by loxP sites, followed by an EGFP gene. If an active Cre is produced in the cells, the dsRED gene will be removed, and the cells will express EGFP and be green. If an active Cre is not produced, the cells will express dsRED only and be red. The red circles in the RG plasmid indicated stop coons. (0049) AT3 cells were transfected with 250 ng RG plasmid, 250 ng EcadCrelllc plasmid, and 1.5 lpg pUC19 as carrier DNA using lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Dt cells were transfected with 100 ng RG plasmid, 100 ng EcadCrelllc plasmid, and 1.8 pg pUC19 as carrier DNA also using lipofectamine according to the manufacturer's instructions. The cells were incubated at 37*C overnight. 19 Atty docket no. 32455/AU-1/ORD (0050) Figure 2B is a picture of the red channel (left panels) and green channel (right panels) of transfected mesenchymal (top panels) and epithelial cells (bottom panels). Green cells were detected in the epithelial cell field, but not in the mesenchymal cell field. (0051) The fraction of EGFP-positive cells was then tracked over time during selection for stable transfectants using hygromycin (selecting for the RG plasmid) and blastocidin (selecting for the EcadCrelllc plasmid). Those results are shown in Figure 2C. At all time points except one, only epithelial cells expressed detectable EGFP. These results suggest that the combination of the E-cadherin promoter and FGFR2 exon Illc effectively limited Cre expression to epithelial cells. Example 3: Synthetic regulation of toxin expression (0052) To determine whether the synthetic regulation systems discussed herein can be used to limit toxin expression to particular cell types, a plasmid was designed to express diphtheria toxin only in epithelial cells. Figure 3A shows plasmid EcadDiplllc, which contains a diphtheria toxin gene with an FGFR2 exon IlIc within the coding region, under the control of the E cadherin promoter. In mesenchymal cells, little transcript will be expressed, and the transcript that is expressed should retain the FGFR2 Illc exon, resulting in an inactive protein product. In epithelial cells, the transcript is more strongly expressed, and the FGFR2 exon Illc is skipped, resulting in active diphtheria toxin protein expression and cell death. (0053) AT3 cells were transfected with 200 or 2,000 ng CMV-Diplllc plasmid and 1.8 or 0 ig pUC19 as carrier DNA using lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. DT cells were transfected with 20 or 100 ng CMV-Dipllic plasmid and 1.95 or 1.9 pg pUC19 as carrier DNA also using lipofectamine according to the manufacturer's instructions. The cells were incubated at 37*C overnight with blasticidin selection, which selects for the CMV-Dipllic plasmid. The presence or absence of the FGFR2 IlIc exon flanked by diphtheria toxin coding sequences was detected in mRNA isolated from the transfected cells using RT-PCR. (0054) The results of that experiment are shown in Figure 3B. In mesenchymal cells, exon IlIc was detected using diphtheria-specific primers, which little or no exon Illc was detected in transcripts from epithelial cells, as would be expected. Little or no transcript lacking exon Illc (and therefore encoding active diphtheria toxin) was detected in epithelial cells, suggesting that the cells that expressed the correctly spliced diphtheria toxin were killed. While not intending to be bound by any particular theory, the surviving epithelial cells may have eliminated the diphtheria toxin-expressing plasmid, may not express the transcript at all, and/or may express a defective diphtheria toxin protein. It should also be noted that transfection efficiency could not be controlled in this experiment. 20 Atty docket no. 32455/AU-1/ORD Example 4: Mesenchymal-specific synthetic regulation of expression (0055) A mesenchymal-specific expression vector was created using a vimentin promoter and by including FGFR2 exons Ilb and Illc. Exon Illb is skipped in mesenchymal cells, while exon Illc is retained. A diagram of the vector is shown in Figure 4A. The vector is shown in the center, with the various splice products shown above and below and labeled i, ii, iii, and iv. Splice product i results from excision of both exons Ilb and lic, and causes a frameshift in exemplary open reading frame (ORF) x and an inactive product. Splice product ii results from inclusion of exon Illb and excision of exon Illc (e.g., in epithelial cells), and results in a transcript with a stop codon ahead of ORF x. Splice product iii results from inclusion of both exons Ilb and Illc, and results in a stop codon ahead of ORF x. Splice product iv results from exclusion of exon Il1b and inclusion of exon Ilic, resulting in a fusion of exon Illc and ORF x in the correct reading frame and an active x fusion protein. Nonlimiting exemplary ORF x include luciferase, GFP, RFP, Cre, and DipA. (0056) AT3 cells grown for one day in 6-well plates were transfected with 250 ng VimllIlbIlIc plasmid and 1.75 pg pUC19 as carrier DNA using lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Dt cells were transfected with 250 ng Vimlllblllc plasmid and 1.75 pg pUC19as carrier DNA also using lipofectamine according to the manufacturer's instructions. The cells were incubated at 37 0 C overnight in low glucose DMEM. RNA was extracted from the cells using RNeasy (Qiagen) and the various splice products amplified by RT-PCR as previously described. See, e.g., Baraniak et al., Mol. Cell Biol. 2006 Feb;26(4):1209-22. The amplified products were then cleaved using Aval or HinclI, which cleave the four splice products in such a way that products of various sizes can be used to identify each of the four splice products. Uncut RT-PCT products separate into a longer band, which corresponds to inclusion of both exons Illb and IlIc ("double inclusion"), and a shorter band, which corresponds to inclusion of either exon Illb or Ilic ("single inclusion"). Aval cleaves once in the Ilb exon. Hincil cleaves twice in the Illc exon. See, e.g., Carstens et al., Mol. Cell Biol., 20(19): 7388-7400 (2000), which is incorporated by reference herein in its entirety for any purpose. (0057) The results of that experiment are shown in Figure 4B. The mesenchymal AT3 cells produced splice product iv, which includes exon Illc only, whereas the epithelial DT cells did not produce appreciable levels of that splice product. Those results confirm that the Vimxlllblllc plasmid produces splice product iv, and presumably an active x fusion protein, in mesenchymal cells, but not epithelial cells. These results also demonstrate that changing the promoter from E-cadherin to vimentin does not affect the specificity of the splicing. 21 Atty docket no. 32455/AU-1/ORD REFERENCES Oltean et al., Clin Exp Metastasis. 2008;25(6):611-9. Seth et al., J Biol Chem. 2008 Apr 11;283(15):10058-67. Black, Cell. 1992 May 29;69(5):795-807. Ladd et al., Mol Cell Biol. 2001 Feb;21(4):1285-96. Ule et al., Nature. 2006 Nov 30;444(7119):580-6. Gallo et al., RNA Biol. 2010 Jul-Aug;7(4):474-9. Kornblihtt et al., FASEB J. 1996 Feb;10(2):248-57. Gallego et al., Biochimie. 1996;78(6):457-65. Gooding et al., Adv Exp Med Biol. 2008;644:27-42. Warzecha et al., RNA Biol. 2009 Nov-Dec;6(5):546-62. Warzecha et al., Mol Cell. 2009 Mar 13;33(5):591-601. Barash et al., Bioinformatics. 2010 Jun 15;26(12):i325-33. Yeo et al., Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20715-9. Black, Annu Rev Biochem. 2003;72:291-336. Tennant et al., Prostate. 2000 Jun 1;43(4):295-302. Baraniak et al., Mol Cell Biol. 2006 Feb;26(4):1209-22. Carstens et al., Mol. Cell Biol. 2000 Oct;20(19):7388-7400. 22

权利要求:
Claims (34)
[1] 1. A synthetic regulatory construct comprising a cell-specific promoter, a heterologous gene, and a cell-specific exon.
[2] 2. The construct of claim 1, wherein the cell-specific exon is excluded in the cell in which the cell-specific promoter is most active.
[3] 3. The construct of claim 2, wherein inclusion of the exon results in the product of the heterologous gene being inactive, or no product of the heterologous gene being produced.
[4] 4. The construct of claim 3, wherein inclusion of the exon results in a frame shift in the heterologous gene or a stop codon before or within the heterologous gene, or both.
[5] 5. The construct of claim 1, wherein the cell-specific exon is included in the cell in which the cell-specific promoter is most active.
[6] 6. The construct of claim 5, wherein exclusion of the exon results in the product of the heterologous gene being inactive, or no product of the heterologous gene being produced.
[7] 7. The construct of claim 6, wherein exclusion of the exon results in a frame shift in the heterologous gene or a stop codon before or within the heterologous gene, or both.
[8] 8. The construct of any one of the preceding claims, wherein the construct further comprises a cell-specific RNA stability element.
[9] 9. The construct of claim 8, wherein the cell-specific RNA stability element is a microRNA target sequence.
[10] 10. The construct of any one of the preceding claims, wherein the cell-specific promoter is at least 2-fold, at least 3-fold, at least 5-fold, at least 7-fold, or at least 10-fold more active in a selected cell than in at least one other cell comprised in the same organism as the selected cell.
[11] 11. The construct of claim 10, wherein the cell-specific promoter is at least 2-fold, at least 3-fold, at least 5-fold, at least 7-fold, or at least 10-fold more active in a selected cell than in at least two, at least three, or at least five other cells comprised in the same organism as the selected cell.
[12] 12. The construct of claim 10, wherein the cell-specific promoter is at least 2-fold, at least 3-fold, at least 5-fold, at least 7-fold, or at least 10-fold more active in a selected cell than in any other cell comprised in the same organism as the selected cell.
[13] 13. The construct of any one of the preceding claims, wherein the cell is an animal cell.
[14] 14. The construct of claim 13, wherein the cell is a mammalian cell. 23 Atty docket no. 32455/AU-1/ORD
[15] 15. The construct of claim 14, wherein the mammal is selected from human, mouse, rat, dog, chimpanzee, and monkey.
[16] 16. The construct of any one of claim 1 to 12, wherein the cell is a plant cell.
[17] 17. The construct of claim 16, wherein the plant is selected from a monocot and a dicot.
[18] 18. A cell comprising the construct of any one of claims 1 to 17.
[19] 19. The cell of claim 18, wherein the cell is an animal cell.
[20] 20. The cell of claim 19, wherein the cell is a mammalian cell.
[21] 21. The cell of claim 20, which is comprised in a mammal.
[22] 22. The cell of claim 20, which is ex vivo or in vitro.
[23] 23. The cell of claim 18, wherein the cell is a plant cell.
[24] 24. The cell of claim 23, which is comprised in a plant.
[25] 25. A method of expressing a heterologous gene in a selected cell comprising introducing a construct of any one of claims 1 to 17 into the selected cell.
[26] 26. The method of claim 18, wherein the selected cell is an animal cell.
[27] 27. The method of claim 19, wherein the animal cell is mammalian cell.
[28] 28. The method of claim 20, wherein the mammal is selected from human, mouse, rat, dog, chimpanzee, and monkey.
[29] 29. The method of claim 20, wherein the selected cell is selected from mesenchymal, epithelial, neuronal, heart muscle, skeletal muscle, smooth muscle, and embryonic muscle.
[30] 30. The method of claim 27, wherein the cell is comprised in a mammal.
[31] 31. The method of claim 18, wherein the selected cell is a plant cell.
[32] 32. The method of claim 23, wherein the plant is selected from a monocot and a dicot.
[33] 33. The method of claim 31, wherein the cell is comprised in a plant.
[34] 34. The method of claim 25, wherein the selected cell is a fungal cell. 24

类似技术:

公开号 | 公开日 | 专利标题

AU2013201287B2|2015-05-14|Synthetic regulation of gene expression

Das et al.2012|Nuclear miRNA regulates the mitochondrial genome in the heart

Ji et al.2009|Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation

Daraselia et al.1996|The promoter for tomato 3-hydroxy-3-methylglutaryl coenzyme A reductase gene 2 has unusual regulatory elements that direct high-level expression

Ribeiro et al.2012|Plasmid DNA size does affect nonviral gene delivery efficiency in stem cells

Dodson et al.1994|An estrogen-inducible protein binds specifically to a sequence in the 3'untranslated region of estrogen-stabilized vitellogenin mRNA

Yamamoto et al.2015|Functional analysis of allene oxide cyclase, MpAOC, in the liverwort Marchantia polymorpha

Fabre et al.1994|Identification of a functional androgen response element in the promoter of the gene for the androgen-regulated aldose reductase-like protein specific to the mouse vas deferens.

Mitsialis et al.1987|A short 5'-flanking DNA region is sufficient for developmentally correct expression of moth chorion genes in Drosophila

Tiago et al.2014|Mir-20a regulates in vitro mineralization and BMP signaling pathway by targeting BMP-2 transcript in fish

Mukai et al.1993|Isolation and characterization of rat CYP11B genes involved in late steps of mineralo-and glucocorticoid syntheses.

Yoshimura et al.2011|High levels of human recombinant cyclooxygenase-1 expression in mammalian cells using a novel gene amplification method

Li et al.2008|Inducible EGFP expression under the control of the nitrate reductase gene promoter in transgenic Dunaliella salina

Zhao et al.2009|The optional long 5′-untranslated region of human ACAT1 mRNAs impairs the production of ACAT1 protein by promoting its mRNA decay

Sano et al.2002|The possible involvement of a phosphate-induced transcription factor encoded by Phi-2 gene from tobacco in ABA-signaling pathways

Mata-Rocha et al.2013|Molecular cloning and analysis of the Catsper1 gene promoter

Ikeno et al.2011|Construction and use of a bottom-up HAC vector for transgene expression

Hiss et al.2017|Combination of the endogenous lhcsr1 promoter and codon usage optimization boosts protein expression in the moss Physcomitrella patens

Matsuura et al.2008|Preferential translation mediated by Hsp81-3 5′-UTR during heat shock involves ribosome entry at the 5′-end rather than an internal site in Arabidopsis suspension cells

Yu et al.2014|Improved site-specific recombinase-based method to produce selectable marker-and vector-backbone-free transgenic cells

Li et al.2009|Establishment of a transgenic pig fetal fibroblast reporter cell line for monitoring Cre recombinase activity

AU2010334886B2|2014-04-24|Promoter sequences

Elango et al.2006|Expression of RUNX2 isoforms: Involvement of cap‐dependent and cap‐independent mechanisms of translation

Hoare et al.2009|Functional characterization of the murine Tnk1 promoter

US20160186196A1|2016-06-30|Method and composition for generating programmed cell death resistant algal cells

同族专利:

公开号 | 公开日

AU2013201287B2|2015-05-14|

US20130254909A1|2013-09-26|

US9284575B2|2016-03-15|

US20160281107A1|2016-09-29|

US9845481B2|2017-12-19|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US5097025A|1989-08-01|1992-03-17|The Rockefeller University|Plant promoters|

US5608144A|1994-08-12|1997-03-04|Dna Plant Technology Corp.|Plant group 2 promoters and uses thereof|

US5880330A|1996-08-07|1999-03-09|The Salk Institute For Biological Studies|Shoot meristem specific promoter sequences|

TW500701B|1999-07-07|2002-09-01|Nippon Sheet Glass Co Ltd|Articles having an uneven surface and production process therefor|

US6291666B1|2000-05-12|2001-09-18|The United States Of America As Represented By The Secretary Of Agriculture|Spike tissue-specific promoter|

WO2002012450A1|2000-08-07|2002-02-14|Texas Tech University|Gossypium hirsutum tissue-specific promoters and their use|

EP1207204A1|2000-11-16|2002-05-22|KWS Saat AG|Tissue-specific promoters from sugar beet|

ES2250358T3|2001-01-17|2006-04-16|Temasek Life Sciences Laboratory Limited|INSULATION AND CHARACTERISTICS OF AN ANTERO-SPECIFIC PROMOTER IN COTTON.|

EP1589813B1|2003-01-03|2015-02-25|The Texas A & M University System|Stem-regulated, plant defense promoter and uses thereof in tissue-specific expression in monocots|

SE0301233D0|2003-04-28|2003-04-28|Swetree Technologies Ab|Tissue specific promoters|

US7238512B2|2003-10-17|2007-07-03|E. I. Du Pont De Nemours And Company|Method to produce para-hydroxybenzoic acid in the stem tissue of green plants by using a tissue-specific promoter|

BR112012000448A2|2009-07-10|2015-10-06|Basf Plant Science Gmbh|expression cassette for regulating seed-specific expression of a transgenic polynucleotide of interest, vector, host cell, plant tissue, plant organ, plant or seed, method for expressing a polynucleotide of interest in a host cell, methods for producing a transgenic plant tissue, plant organ, plant, or seed and use of the expression cassette|

US9284575B2|2012-03-06|2016-03-15|Duke University|Synthetic regulation of gene expression|US9284575B2|2012-03-06|2016-03-15|Duke University|Synthetic regulation of gene expression|

RU2016102922A|2013-06-29|2017-08-03|Фирмениш Са|METHODS FOR IDENTIFICATION, ISOLATION AND APPLICATION OF RECEPTORS OF FRAGRANT SUBSTANCES AND AROMAS|

WO2015157306A1|2014-04-09|2015-10-15|University Of Houston|Therapeutic mirnas for treating heart and skeletal muscle diseases|

US10210380B2|2016-08-09|2019-02-19|Daon Holdings Limited|Methods and systems for enhancing user liveness detection|

US10628661B2|2016-08-09|2020-04-21|Daon Holdings Limited|Methods and systems for determining user liveness and verifying user identities|

US11115408B2|2016-08-09|2021-09-07|Daon Holdings Limited|Methods and systems for determining user liveness and verifying user identities|

US10217009B2|2016-08-09|2019-02-26|Daon Holdings Limited|Methods and systems for enhancing user liveness detection|

KR20190137126A|2017-04-03|2019-12-10|엔코디드 테라퓨틱스, 인크.|Tissue Selective Transgene Expression|

WO2020168279A2|2019-02-15|2020-08-20|Allen Institute|Artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations|

WO2021016075A1|2019-07-19|2021-01-28|Flagship Pioneering Innovations Vi, Llc|Recombinase compositions and methods of use|

法律状态:
2015-09-10| FGA| Letters patent sealed or granted (standard patent)|

2017-09-28| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|

优先权:

申请号 | 申请日 | 专利标题

US201261607312P| true| 2012-03-06|2012-03-06||

US61/607,312||2012-03-06||

[返回顶部]